GI Symptoms Common in Patients With Cancer and COVID-19
Investigators evaluated the prevalence and severity of gastrointestinal symptoms in patients with COVID-19 and cancer who were hospitalized during the study period.
Investigators evaluated the prevalence and severity of gastrointestinal symptoms in patients with COVID-19 and cancer who were hospitalized during the study period.
Cancer incidence trends across 41 countries demonstrated sharp increases and decreases in certain cancer types over the last 15 years.
Antibiotic use prior to ICI treatment may reduce ICI efficacy and result in worse survival outcomes among patients with cancer, in a retrospective study.
Preliminary data suggest that neoadjuvant treatment of resected pancreatic cancer with urelumab plus nivolumab and GVAX was well tolerated and showed some antitumor activity in a small study.
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.
First-line pembrolizumab plus chemotherapy prolonged survival among patients with advanced esophageal or esophagogastric junction cancer.
Nivolumab plus chemotherapy prolonged survival of patients with advanced gastric, gastroesophageal junction, and esophageal cancers compared with chemotherapy.
Cabozantinib prolonged survival compared with placebo regardless of baseline AFP levels. Lower baseline AFP levels associated with the longest survival.